Chemoradiotherapy With Adjuvant Chemotherapy for Advanced Cervical Cancer
Tests extra chemotherapy after radiotherapy and chemotherapy in adults with advanced cervical cancer.
Plain-language title generated from the registry record
Registry title: Concurrent Chemoradiotherapy Combined With Adjuvant Chemotherapy Treated Advanced Cervical Cancer
Key facts
- Where
- Liuzhou, ChinaSee the site
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 18-75 with locally advanced cervical cancer whose cancer has fully responded (CR) to chemoradiotherapy with afterloading treatment. It tests adding chemotherapy afterwards.
- Age
- 18-75 years
- Sex
- Women only
- Disease stage
- Cervical cancer (squamous cell, adenocarcinoma or adenosquamous) at FIGO 2018 stage IB3, IIA2, or IIB-IVA, with complete response (CR) after standard concurrent chemoradiotherapy and afterloading treatment.
- Earlier treatment
- Must have had standard concurrent intensity-modulated chemoradiotherapy followed by three-dimensional afterloading treatment, with complete response. Cannot have had neoadjuvant chemotherapy or surgery.
Main reasons for not taking part
- Cancer did not reach complete response after chemoradiotherapy
- Neoadjuvant chemotherapy or surgery before
- Any distant metastases
- Another cancer within 5 years
- Pregnant or breastfeeding, or able to become pregnant without using contraception
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT05735145, who can take part
Where in China
- the Fourth Affiliated Hospital of Guangxi Medical UniversityLiuzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Fourth Affiliated Hospital of Guangxi Medical University
- Trial code
- NCT05735145
- Record updated
- 21 February 2023
- Original description
This study carried out a prospective, randomized, controlled clinical study under the background of intensity-modulated radiation therapy and three-dimensional afterloading therapy. By comparing simultaneous intensity-modulated radiotherapy and chemotherapy combined with adjuvant chemotherapy and simultaneous intensity-modulated radiotherapy and chemotherapy alone, based on the 2018 FIGO staging The clinical efficacy of locally advanced cervical cancer further clarifies the role of adjuvant chemotherapy in locally advanced cervical cancer.Read full original descriptionShow less
A Prospective Randomized Controlled Trial for Concurrent Chemoradiotherapy Combined With Adjuvant Chemotherapy in the Treatment of Advanced Cervical Cancer at 2018 FIGO Staging
This study carried out a prospective, randomized, controlled clinical study under the background of intensity-modulated radiation therapy and three-dimensional afterloading therapy. By comparing simultaneous intensity-modulated radiotherapy and chemotherapy combined with adjuvant chemotherapy and simultaneous intensity-modulated radiotherapy and chemotherapy alone, based on the 2018 FIGO staging The clinical efficacy of locally advanced cervical cancer further clarifies the role of adjuvant chemotherapy in locally advanced cervical cancer.
Inclusion: Cervical cancer confirmed by histopathology incloud squamous cell carcinoma, adenocarcinoma and adenosquamous carcinoma; FIGO stage IB3, IIA2, IIB-IVA patients in 2018; Locally advanced cervical cancer patients received standard concurrent intensity-modulated chemoradiotherapy followed by three-dimensional afterloading treatment after diagnosis, and the effect reached CR after treatment; Aged 18-75 years; PS score 0-1; Serum hemoglobin >=100*10\^9/L, blood platelet >= 100000/μL, absolute count of neutrophils>=1500/μL; 7.Serum creatinine <=1.5 UNL or creatinine clearance >= 60 ml/min; 8.Serum bilirubin <=1.5 UNL, AST (SGOT) and ALT (SGPT)<= 1.5 UNL; Sign a formal informed consent to show that they understand that the study is in line with hospital and national policies .Estimated total survival > 6 months.
Exclusion: Locally advanced cervical cancer patients received standard concurrent intensity-modulated chemoradiotherapy followed by three-dimensional afterloading treatment after diagnosis, and the effect unreached CR after treatment; Patients who have received neoadjuvant chemotherapy and surgery; Drug abusers or alcohol addicts; Patients with cognitive impairment; Patients with any other malignancy within 5 years; Any other disease or condition is contraindications to chemoradiotherapy (e.g., active infection, 6 months after myocardial infarction, symptomatic heart disease, including unstable angina, congestive heart failure or uncontrolled arrhythmias, immunosuppressive therapy, etc.); 5.Pregnant or lactating women, or fertile women who do not use contraception; Patients with bleeding tendency; Those who are known to have a third or fourth degree allergic reaction to any treatment in the study; Patients with any distant metastases; Severe bone marrow dysfunction.